#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Marfan's syndrome Arteriosclerosis Neuroendocrine cell hyperplasia of infancy Transplant rejection Haemophilia A without inhibitors Progressive familial intrahepatic cholestasis Still's disease Undifferentiated sarcoma Extra-osseous Ewing's sarcoma Hereditary motor and sensory neuropathy Epilepsy with myoclonic-atonic seizures Hodgkin's disease refractory Epidermolysis bullosa Idiopathic intracranial hypertension Kawasaki's disease More trials…

    Learn about Rare Diseases

    Richter’s syndrome – Diagnostics Urea cycle disorder – Life with Disease Wiskott-Aldrich syndrome – Trials in Disease Proteus syndrome – Basic Information Cystic fibrosis lung – Diagnostics Nephrotic syndrome Synovial sarcoma Atypical teratoid/rhabdoid tumour of CNS – Treatment Haemophilia B without inhibitors – Life with Disease Isodicentric chromosome 15 syndrome – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Cilazapril Ianalumab Pseudoephedrine Hydrochloride Magnesium Citrate Mps-103 68Ganota-Anti-Her2 Vhh1 Amiloride Cefalexin Atuliflapon ZIMISLECEL Zongertinib GSKVX000000039711 Vx-670 Fluoxetine Imifoplatin Carbasalate Calcium Ecoo2 XMAB942 Gsk4527226 Larotrectinib Sulfate More therapies…

    Learn about Your Condition

    Bone hypertrophy Arthritis infective Osteogenesis imperfecta Hepatitis D Perineal injury Kearns-Sayre syndrome Anal fissure Post cardiac arrest syndrome Parkinson's disease Alcohol abuse Bacterial infection Traumatic pain Post-traumatic headache Hypophosphatasia Pain More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Uncategorized

  • Study Comparing Metformin and Tolvaptan for Adults with Autosomal Dominant Polycystic Kidney Disease (ADPKD)

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Congenital cystic kidney disease
    Investigated Drugs:
    • Metformin
    • Tolvaptan
    Italy

  • Study on the Effects of Metolazone, Acetazolamide, and a Drug Combination for Patients with Chronic Heart Failure

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Metolazone
    • Acetazolamide
    Italy

  • Study on the Effectiveness and Safety of Alpelisib for Patients with Dent 2 Disease

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Dent’s disease
    Investigated Drugs:
    • Alpelisib
    Italy

  • Study on the Effectiveness and Safety of BAY 2927088 for Patients with Advanced Solid Tumors with HER2 Mutations

    Recruiting

    2 1 1
    Investigated Diseases:
    • Gastrointestinal carcinoma
    • Malignant neoplasm of ampulla of Vater
    • Salivary gland cancer
    Investigated Drugs:
    • 3-(3-CHLORO-2-METHOXYANILINO)-2-{3-[(2S)-1,4-DIOXAN-2-YLMETHOXY]PYRIDIN-4-YL}-1,5,6,7-TETRAHYDRO-4H-PYRROLO[3,2-C]PYRIDIN-4-ONE
    • Bay 2927088
    • SEVABERTINIB
    Denmark France Italy Spain

  • Study on Atezolizumab for Patients with Malignant Pleural Mesothelioma After Surgery

    Recruiting

    3 1 1
    Investigated Diseases:
    • Pleural mesothelioma malignant
    Investigated Drugs:
    • Atezolizumab
    Italy

  • Study on Clindamycin and Rifampicin for Treating Infections in Patients with Obesity, Fracture-Related Infections, Hidradenitis Suppurativa, or Prosthetic Joint Infections

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Fracture infection
    • Medical device site joint infection
    Investigated Drugs:
    • Clindamycin Hydrochloride
    • Rifampicin
    Belgium
Previous Page
1 … 269 270 271 272 273 … 1,648
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!